All News
EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks
The EMA has updated recommendations regarding the use of JAK inhibitors by issuing a direct healthcare professional communication summarizing the data and warnings regarding an increased risk of malignancy, major adverse cardiovascular events (MACE), serious infections, VTE, and mortality in some patients receiving JAKi for the treatment of chronic inflammatory disorders.
Read Article
Psoriatic Arthritis and Pregnancy
At RheumNow Live this weekend, Dr. Christina Chambers, an epidemiologist at the University of California San Diego and the principal investigator of MotherToBaby Pregnancy Studies, reviewed the available data on psoriatic arthritis and pregnancy. There is little evidence at this time that pregnancy affects PsA, though studies reliably demonstrate increase in disease activity in the post-partum period in both skin and joint disease.
Read Article
Drs. Tate and Dao will be leading discussions on Women in Rheumatology, the XX Factor.
Sign up to attend our Tuesday Night Rheumatology series.
@uptoTate @KDAO2011
https://t.co/ciEAY1SJdg https://t.co/dlCfXItAxN
Links:
Dr. John Cush RheumNow ( View Tweet)
Tomorrow! Join us for Tuesday Night Rheumatology.
Our panelists will discuss the challenges they have faced trying to manage a career and family life, as well as provide advice and strategies for managing competing priorities and obligations.
https://t.co/OlP0pupkMV https://t.co/pZQMASafcG
Links:
Dr. John Cush RheumNow ( View Tweet)
The EMA Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, regarding the marketing authorisation of deucravacitinib (Sotyktu) in the treatment of moderate to severe psoriasis based on the POETYK PSO-1 & POETYK PSO-2 RCTs https://t.co/KBIYSJVFqu
. https://t.co/nzuHh6v0ua
Links:
Dr. John Cush RheumNow ( View Tweet)
Small trial of MTX vs Apremilast in PsA from India. OL, MD blinded RCT of 31 pts (26 completed). 15 APR vs 16 MTX (had more enthesitis, dactylitis); wk 24 responses favored MTX for major cDAPSA (37% vs 20%; p=0.4), ACR20 (56 v 47%;NS) w/ no diff in AE https://t.co/KIItKgCq4w https://t.co/FG3NV2yLuc
Links:
Dr. John Cush RheumNow ( View Tweet)
199 psoriasis Pts Rx w/ MTX monotherapy. Drug survival at 1, 2, & 5 yrs was 47, 36, & 29%; Avg MTX duration was 10.1 mos. Discontinuation mostly for AE (39.2%), ineffective (38.5%), PSO remission (12.2%). Durability best w/ ^age & dose >15 mg https://t.co/zKP0QCDzE2 https://t.co/35neGlhpE5
Links:
Dr. John Cush RheumNow ( View Tweet)
Treat to target approach in PsA
Systematic rev: 12-43% pts achieved target of very low disease activity or remission
Pts and docs agree: remission is primary goal, but Low disease activity is acceptable alternative
@DrLauraCoates at #RNL2023
https://t.co/XyXBAn82F1 https://t.co/W0nVdq6urq
Links:
Dr. John Cush RheumNow ( View Tweet)
Have a Rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/MMHvtkbz9l https://t.co/3aNijNJWkW
Links:
Dr. John Cush RheumNow ( View Tweet)
Polypharmacy Increased in Psoriatic Arthritis
Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA.
https://t.co/vispc9ei51 https://t.co/s45Nmpf46P
Links:
Dr. John Cush RheumNow ( View Tweet)
@RheumNow's review of new drug approvals during 2022 at #RNL2023 https://t.co/IgndlG6lOI
Dr. Rachel Tate uptoTate ( View Tweet)
Biosimilars are coming!
Multiple adalimumab biosimilars this year
- will we see a dramatic price difference?
@RheumNow #RNL2023 https://t.co/8vdtXtEGOO
Robert B Chao, MD doctorRBC ( View Tweet)
Biosimilar to biosimilar switching of Infliximab , @RheumNow Kavanaugh #RNL2023
Communications is a key always.
Discuss with your patient always, and show them the data. https://t.co/d7Nq6LoJYQ
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Risk of adverse outcomes in PsA pregnancies
More pre eclampsia
More Cesarian section
More preterms
By Dr.Chambers #RNL2023 @RheumNow https://t.co/LRiSSpv4Yj
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Dr. Eric Ruderman with an excellent review of the JAK/STAT pathway especially for PsA treatment
@RheumNow #RNL2023 https://t.co/kNDouZ4kCV
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023 Year in Review
COMPLETE-PsA: DMARDs for PsA!
LEF+MTX better than MTX alone, 78 total patients
PASDAS at week 16: 59% for MTX+LEF vs 34% MTX+PBO
More treatment discontinuations (10 vs 3) in combo group due to GI intolerance
@RheumNow https://t.co/3Al8PQmNli
Eric Dein ericdeinmd ( View Tweet)
Check out MothertoBaby fact sheets by the NIH and LactRX (by mother to baby) app for pregnancy, disease, and medications. Dr. C. Chambers highlighted this today at #RNL2023 @RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
#RNL2023 Year in Review
Male response better than female response in patients with PsA in SELECT-PsA evaluating UPA/ADA.
More targeted studies needed
@RheumNow https://t.co/Z3kbM0e9A0
Eric Dein ericdeinmd ( View Tweet)
#RNL2023 Year in Review
BE COMPLETE: P3 trial Bimekizumab for PsA in TNF inadequate responses at 16 weeks
160 mg BKZ SQ q4w vs PBO
ACR50 43%, PBO 7%
PASI 1000: BKZ 58.5% vs PBO 4.5%
Safety: oral candidiasis: 2.6% BKZ vs PBO 0%
@RheumNow https://t.co/bW00Wg6Cnf
Eric Dein ericdeinmd ( View Tweet)
Talk to me about candidiasis. BKZ showed increased safety signals for candida infections. I fear infxns may be under reported (after approval and in use) if patients see other physicians for treatment vs their rheumatologist/derm. Thoughts on this signal? #RNL2023 @rheumnow https://t.co/UPA5oP9G49
Dr. Rachel Tate uptoTate ( View Tweet)
